Valeant Pharmaceuticals To Appoint Robert L. Rosiello As Chief Financial Officer

June 11, 2015

Valeant Pharmaceuticals International, Inc. announced today that Robert L. Rosiello was appointed as Executive Vice President and will take over the role of Chief Financial Officer on July 1, 2015.

PRESS RELEASE

LAVAL, Quebec

,

June 11, 2015

/PRNewswire/ --

Valeant Pharmaceuticals International, Inc.

(NYSE: VRX) (TSX: VRX) announced today that

Robert L. Rosiello

was appointed as Executive Vice President and will take over the role of Chief Financial Officer from

Howard Schiller

on

July 1

, 2015. Mr. Schiller will remain on Valeant's Board and is expected to serve as a consultant to Valeant.

"The Board of Directors and I are delighted that Rob has agreed to join Valeant," said

J. Michael Pearson

, Chairman and Chief Executive Officer. "Rob is someone I have worked closely with for 20 years. I know his tremendous expertise in healthcare and in particular M&A, his unquestioned intellect, and work ethic and integrity will prove to be of great value to the Valeant organization and its shareholders. I want to thank Howard for his strong leadership to both myself and the entire organization these past few years and I will continue to rely on his valuable counsel as a member of our Board of Directors."

Mr. Rosiello worked 30 years at

McKinsey & Company

helping healthcare, technology and consumer companies deliver growth through M&A and business unit financial performance improvement. As Senior Partner in charge of the global merger practice for the past decade, Mr. Rosiello led M&A integrations for pharmaceutical, specialty pharmaceutical and medical device companies in the U.S.,

Europe

and

Asia

.

Mr. Rosiello serves on the Board of

Catholic Charities of New York

, the

Pew Research Center

and the

Central Selection Committee

of the

Morehead Cain Foundation

. He received his BA in economics from the

University of North Carolina

, where he was a Morehead Scholar. He also earned an MS from the

London School of Economics

and an MBA from

Harvard

.